Decheng Capital Management III (Cayman)’s Arcus Biosciences RCUS Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$15.6M	Hold	869,790	–	–	5.21%	6
2023 Q2	$17.7M	Hold	869,790	–	–	5.54%	6
2023 Q1	$15.9M	Hold	869,790	–	–	6.4%	8
2022 Q4	$18M	Hold	869,790	–	–	6.73%	5
2022 Q3	$22.8M	Hold	869,790	–	–	8.25%	5
2022 Q2	$22M	Hold	869,790	–	–	8.36%	5
2022 Q1	$27.5M	Buy	+869,790	New	+$29.1M	8.41%	4

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s RCUS Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) held its Arcus Biosciences (RCUS) position steady in Q3 2023 at 869,790 shares worth $15.6M. The position accounts for 5.21% of the portfolio, ranked #6.

Decheng Capital Management III (Cayman) first reported a position in RCUS in Q1 2022 and has held it in 7 quarters since. The position peaked at $27.5M in Q1 2022. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2023.

Decheng Capital Management III (Cayman) held 869,790 shares of Arcus Biosciences worth $15.6M as of Q3 2023.
Decheng Capital Management III (Cayman) left its Arcus Biosciences share count unchanged in Q3 2023.
Arcus Biosciences made up 5.21% of Decheng Capital Management III (Cayman)'s portfolio in Q3 2023, its #6 holding.
Decheng Capital Management III (Cayman) first reported a position in Arcus Biosciences in Q1 2022 and has held it in 7 quarters since.
Decheng Capital Management III (Cayman)'s Arcus Biosciences position peaked at $27.5M in Q1 2022.
187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.